Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JONATHAN S ILOWITE

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1356403364
CMS profile
288011
Location
NEW HYDE PARK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$1,849.01

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Boehringer Ingelheim Pharmaceuticals, Inc. $1,849.01 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JONATHAN S ILOWITE

NPI 1356403364 · CMS profile ID 288011

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

NEW HYDE PARK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1356403364?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JONATHAN S ILOWITE, NPI 1356403364, CMS profile ID 288011. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356403364?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). JONATHAN S ILOWITE, NPI 1356403364, CMS profile ID 288011. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356403364?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
JONATHAN S ILOWITE, NPI 1356403364, CMS profile ID 288011, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1356403364?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $1,849.01 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $1,849.0107/08/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720515093 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $1,849.01 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020
Generated from
OP_DTL_GNRL_PGYR2020_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

This record has limited reported data across the program years shown and is not featured in search indexes. The records below are complete; see the methodology for how featured pages are determined.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $55,453.36 13
PY2024 Principal investigator $96,271.40 77
PY2023 Principal investigator $77,314.74 41
PY2022 Principal investigator $92,991.92 43
PY2021 Principal investigator $201,603.87 45
PY2020 Principal investigator $61,126.56 5
PY2019 Principal investigator $116,156.75 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

77 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $285.69 12/31/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
A Phase III Multicentre Randomised Double blind Chronic dosing Parallel group Placebo controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease COPD with a History of COPD Exacerbations OBERON No dispute reported 06/30/2026 1155802514
Principal investigator 1 GlaxoSmithKline, LLC. $937.80 12/11/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1156002331
Principal investigator 1 GlaxoSmithKline, LLC. $2,248.20 11/06/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127537980
Principal investigator 1 GlaxoSmithKline, LLC. $1,396.80 10/04/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127537974
Principal investigator 1 Insmed, Inc. $1,360.00 10/01/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067596826
Principal investigator 1 Insmed, Inc. $1,500.00 10/01/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607558
Principal investigator 1 Insmed, Inc. $1,500.00 10/01/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607560
Principal investigator 1 GlaxoSmithKline, LLC. $945.00 09/06/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127537978
Principal investigator 1 Insmed, Inc. $10.20 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067591330
Principal investigator 1 Insmed, Inc. $241.40 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067591332
Principal investigator 1 Insmed, Inc. $236.78 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067591334
Principal investigator 1 Insmed, Inc. $245.62 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067591336
Principal investigator 1 Insmed, Inc. $229.98 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067591338
Principal investigator 1 Insmed, Inc. $241.40 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067591340
Principal investigator 1 Insmed, Inc. $69.36 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067591342
Principal investigator 1 Insmed, Inc. $160.48 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067591344
Principal investigator 1 Insmed, Inc. $69.36 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067591346
Principal investigator 1 Insmed, Inc. $81.06 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067591348
Principal investigator 1 Insmed, Inc. $242.08 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067591350
Principal investigator 1 Insmed, Inc. $338.64 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067591352
Principal investigator 1 Insmed, Inc. $242.08 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067591354
Principal investigator 1 Insmed, Inc. $6.12 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067596808
Principal investigator 1 Insmed, Inc. $81.06 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067596810
Principal investigator 1 Insmed, Inc. $242.08 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067596812
Principal investigator 1 Insmed, Inc. $20.40 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067596814
Principal investigator 1 Insmed, Inc. $4.76 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067596816
Principal investigator 1 Insmed, Inc. $245.62 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067596818
Principal investigator 1 Insmed, Inc. $69.36 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067596820
Principal investigator 1 Insmed, Inc. $236.78 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067596822
Principal investigator 1 Insmed, Inc. $242.08 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067596824
Principal investigator 1 Insmed, Inc. $20.40 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602154
Principal investigator 1 Insmed, Inc. $160.48 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602156
Principal investigator 1 Insmed, Inc. $81.06 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602158
Principal investigator 1 Insmed, Inc. $69.36 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602160
Principal investigator 1 Insmed, Inc. $208.08 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602162
Principal investigator 1 Insmed, Inc. $81.06 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602164
Principal investigator 1 Insmed, Inc. $208.08 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602166
Principal investigator 1 Insmed, Inc. $338.64 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602168
Principal investigator 1 Insmed, Inc. $229.98 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607538
Principal investigator 1 Insmed, Inc. $81.06 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607540
Principal investigator 1 Insmed, Inc. $212.30 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607542
Principal investigator 1 Insmed, Inc. $81.06 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607544
Principal investigator 1 Insmed, Inc. $199.38 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607546
Principal investigator 1 Insmed, Inc. $338.64 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607548
Principal investigator 1 Insmed, Inc. $6.80 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607550
Principal investigator 1 Insmed, Inc. $338.64 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607552
Principal investigator 1 Insmed, Inc. $195.16 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607554
Principal investigator 1 Insmed, Inc. $195.16 09/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607556
Principal investigator 1 GlaxoSmithKline, LLC. $3,548.70 08/14/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127521840
Principal investigator 1 GlaxoSmithKline, LLC. $1,247.40 07/08/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127521838
Principal investigator 1 Insmed, Inc. $105.26 06/28/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067591328
Principal investigator 1 Insmed, Inc. $37.94 06/28/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067596802
Principal investigator 1 Insmed, Inc. $37.94 06/28/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067596804
Principal investigator 1 Insmed, Inc. $37.94 06/28/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067596806
Principal investigator 1 Insmed, Inc. $37.94 06/28/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602148
Principal investigator 1 Insmed, Inc. $105.26 06/28/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602150
Principal investigator 1 Insmed, Inc. $37.94 06/28/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602152
Principal investigator 1 Insmed, Inc. $37.94 06/28/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607532
Principal investigator 1 Insmed, Inc. $105.26 06/28/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607534
Principal investigator 1 Insmed, Inc. $105.26 06/28/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607536
Principal investigator 1 GlaxoSmithKline, LLC. $970.00 06/21/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127521834
Principal investigator 1 GlaxoSmithKline, LLC. $11,444.00 06/21/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127537968
Principal investigator 1 GlaxoSmithKline, LLC. $4,739.40 06/14/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127537964
Principal investigator 1 GlaxoSmithKline, LLC. $4,579.20 05/08/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127521842
Principal investigator 1 GlaxoSmithKline, LLC. $2,839.50 04/15/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127521844
Principal investigator 1 GlaxoSmithKline, LLC. $2,250.00 04/05/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127537962
Principal investigator 1 Insmed, Inc. $400.00 04/02/2024 Non-covered Recipient Entity
The Feinstein Institutes for Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602146
Principal investigator 1 GlaxoSmithKline, LLC. $3,272.40 03/13/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127537966
Principal investigator 1 GlaxoSmithKline, LLC. $4,144.00 03/06/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127537972
Principal investigator 1 SANOFI US SERVICES INC. $6,642.00 03/04/2024 Non-covered Recipient Entity
Biomedical Research Alliance Of New York LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 1128717979
Principal investigator 1 GlaxoSmithKline, LLC. $925.00 02/09/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127521836
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,442.00 02/07/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
Phase III study is to evaluate the efficacy and safety of Tozorakimab MEDI3506 Dose 1 and Dose 2 administered subcutaneously SC in adult participants with symptomatic COPD and history of 2 moderate or 1 severe exacerbation of COPD in the previous 12 months No dispute reported 06/30/2026 1110846425
Principal investigator 1 GlaxoSmithKline, LLC. $4,859.10 02/02/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127537976
Principal investigator 1 SANOFI US SERVICES INC. $925.00 01/29/2024 Non-covered Recipient Entity
Biomedical Research Alliance Of New York LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 1128717963
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,738.69 01/24/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibod No dispute reported 06/30/2026 1110834929
Principal investigator 1 GlaxoSmithKline, LLC. $9,955.80 01/12/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127537970
Principal investigator 1 GlaxoSmithKline, LLC. $925.00 01/10/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127537960